107017-73-2

Usage

Mechanism of action

User reports indicate that ephylone produces a mixture of classic stimulant and entactogenic effects resembling those of MDMA, methylone and cocaine. Typical effects include stimulation, disinhibition, increased libido, compulsive redosing, and euphoria. Unlike similar substances, however, ephylone is reported to be very long lasting when taken in larger doses. The significance of this is not known, although it may indicate that it has a different toxicity profile compared to other stimulants. Ephylone is sold online as a research chemical alongside other synthetic cathinones like ethylone and dibutylone. Due to the lack of research, it is highly advised to use harm reduction practices if using this substance.

Upstream product

• 1159737-77-5 C₁₄H₂₃NO₆ 
• 88950-64-5 1-<(tert-butyloxy)carbonylamino>cyclopropane-1-carboxylic acid 
• 543-27-1 isobutyl chloroformate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 115652-52-3 1-amino-1-(hydroxymethyl)cyclopropane hydrochloride 
• 944143-85-5 C₁₁H₂₁NO₃ 
• 925-90-6 ethylmagnesium bromide 
• 66494-26-6 methyl 1-[[(tert-butoxy)carbonyl]amino]cyclopropane-1-carboxylate 
• 308266-24-2 (N-tert-butoxycarbonyl)-1-(benzyloxymethyl)cyclopropylamine 
• 107259-05-2 1-tert-butoxycarbonylamino-cyclopropanecarboxylic Acid Ethyl Ester 

Downstream Products

• 387845-49-0 tert-butyl (1-(bromomethyl)cyclopropyl)carbamate 
• 1268810-09-8 tert-butyl N-(1-ethynylcyclopropyl)carbamate 
• 387845-50-3 tert-butyl 1-(cyanomethyl)cyclopropylcarbamate 

Relevant academic research and scientific papers

Titanium-catalyzed cyclopropanation of Boc-protected cyanohydrins: A short access to aminocyclopropanecarboxylic acid derivatives

The preparation of protected 1-aminocyclopropanecarboxylic acid was performed from readily available and inexpensive starting materials, using titanium-catalyzed cyclopropanation as the key step. As an extension of this methodology, a diastereoselective synthesis of the cis-2-vinyl-substituted analogue is presented. Georg Thieme Verlag Stuttgart.

New "Ofloxacin" Type Antibacterial Agents. Incorporation of the Spiro Cyclopropyl Group at N-1

The first example incorporating a spiro cyclopropyl group into an "ofloxacin" type of quinolone antibacterial agent has been prepared by potassium fluoride mediated ring closure of the hydroxymethyl cyclopropyl intermediate to give 9'-fluoro-7'-oxo-10'-(1-piperazinyl)spiropyridobenzoxazine>-6'-carboxylic acid.Analogues were made by substitution at C-7 by various complex amines.Evaluation of these compounds for antibacterial activity was carried out.All examples prepared and examined showed in vitro minimum inhibitory values and in vivo mouse protection results to be diminished as compared to the parent, ofloxacin.

SUBSTITUTED TRIAZINONES AS THYROID HORMONE RECEPTOR AGONISTS

The application relates to a compound of Formula (I') or (I), or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I') or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.

TYK2 INHIBITORS AND USES THEREOF

Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS

The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS

The disclosure relates to compounds of formula (I), which are formyl peptide 2 (FPR2) receptor agonists and/or formyl peptide 1 (FPRl) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the tr

SUBSTITUTED 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE ANTIBACTERIAL COMPOUNDS

The invention relates to antibacterial compounds of formula (I) wherein M is one of the groups MA, MB and MC represented below wherein R1, MA, MB and MC are as defined in the specification; and to salts thereof.

SUBSTITUTED 3,4-DIHYDROPYRROLO[1,2-A]PYRAZIN-1 (2H)-ONE DERIVATIVES AS KINASE INHIBITORS

Compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2, R3, R4, R5 and R6 have any of the meanings defined hereinbefore in the description, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cancer are disclosed.

IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AS KINASE INHIBITORS

The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which is useful in the treatment of a tumor through its ROS1 kinase enzyme activity inhibitory effect and NTRK kinase enzyme inhibitory effect. The present invention provides a compound having an imidazo[1,2-b]pyridazine structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, G, T, Y1, Y2, Y3, and Y4 are as defined herein.

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.